Freemont Management S.A. Increases Stake in Axon Enterprise, Inc $AXON

Freemont Management S.A. increased its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 200.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 3,600 shares of the biotechnology company’s stock after acquiring an additional 2,400 shares during the period. Freemont Management S.A.’s holdings in Axon Enterprise were worth $2,045,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in AXON. Evergreen Capital Management LLC boosted its position in Axon Enterprise by 3.8% during the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock valued at $342,000 after buying an additional 15 shares during the period. NorthCrest Asset Manangement LLC raised its stake in shares of Axon Enterprise by 5.4% during the third quarter. NorthCrest Asset Manangement LLC now owns 313 shares of the biotechnology company’s stock valued at $223,000 after acquiring an additional 16 shares during the last quarter. WPG Advisers LLC raised its stake in shares of Axon Enterprise by 9.8% during the third quarter. WPG Advisers LLC now owns 190 shares of the biotechnology company’s stock valued at $136,000 after acquiring an additional 17 shares during the last quarter. Monte Financial Group LLC raised its stake in shares of Axon Enterprise by 5.5% during the third quarter. Monte Financial Group LLC now owns 325 shares of the biotechnology company’s stock valued at $233,000 after acquiring an additional 17 shares during the last quarter. Finally, Wealth Alliance LLC raised its stake in shares of Axon Enterprise by 3.2% during the third quarter. Wealth Alliance LLC now owns 583 shares of the biotechnology company’s stock valued at $419,000 after acquiring an additional 18 shares during the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Stock Down 4.3%

Shares of NASDAQ AXON opened at $376.82 on Thursday. The company has a current ratio of 2.27, a quick ratio of 1.93 and a debt-to-equity ratio of 0.49. Axon Enterprise, Inc has a 12 month low of $339.01 and a 12 month high of $885.91. The firm has a market capitalization of $30.37 billion, a PE ratio of 151.33, a price-to-earnings-growth ratio of 9.26 and a beta of 1.44. The firm has a fifty day simple moving average of $439.60 and a two-hundred day simple moving average of $518.79.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 EPS for the quarter, topping the consensus estimate of $1.60 by $0.01. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The business had revenue of $807.35 million during the quarter, compared to analyst estimates of $778.91 million. During the same period in the prior year, the business earned $1.47 EPS. The company’s revenue for the quarter was up 33.7% on a year-over-year basis. Equities analysts expect that Axon Enterprise, Inc will post 1.41 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. TD Cowen lowered their price objective on shares of Axon Enterprise from $950.00 to $825.00 and set a “buy” rating for the company in a research note on Wednesday, April 8th. Morgan Stanley set a $600.00 price objective on shares of Axon Enterprise in a research note on Thursday, May 7th. UBS Group lowered their price objective on shares of Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating for the company in a research note on Thursday, May 7th. Needham & Company LLC lowered their price objective on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a research note on Friday, February 20th. Finally, Barclays lowered their price objective on shares of Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Sixteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $712.75.

Insiders Place Their Bets

In other Axon Enterprise news, insider Isaiah Fields sold 2,000 shares of the company’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $535.01, for a total value of $1,070,020.00. Following the completion of the transaction, the insider directly owned 55,588 shares in the company, valued at approximately $29,740,135.88. This represents a 3.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Patrick W. Smith sold 10,000 shares of the company’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $500.24, for a total transaction of $5,002,400.00. Following the completion of the transaction, the chief executive officer owned 3,090,997 shares of the company’s stock, valued at $1,546,240,339.28. This trade represents a 0.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 13,855 shares of company stock worth $7,109,828. Company insiders own 4.40% of the company’s stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.